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Studying Cardiovascular Disease 
Using Human Stem Cell-derived 3D 
Cardiomyocytes 
Nicholas Dash ‘20, Veronica Bohl ‘20, and Dr. Charles Toth 
What are cardiomyocytes?
Cardiomyocytes are the cells that make the heart contract. They are essential for the 
heart to beat.
Why this experiment?
Heart disease is the leading cause of death in both men and women in the United 
States. This experiment provides insight on how using metabolites derived naturally 
from the microbiome can influence cardiac inflammation.
3D cardiomyocytes were derived from human induced pluripotent stem cells 
through the utilization of small molecules and growth factors. Quantitative PCR 
was performed to verify that the organoids expressed genes associated with 
cardiomyocyte cells. Primers for the genes FOXa2, TNNT2, MYH7, AHR, 
CACNA1, and KCNH2 were used for the qPCR, as these genes are expressed 
more prominently in cardiomyocyte cells than the undifferentiated iPSCs.
Procedure:
Cardiovascular disease was modeled by inducing inflammation in the organoids 
using lipopolysaccharide (LPS), a gram-negative bacteria membrane product 
associated with inflammation and septic shock, indoxyl-3-sulfate (I3S), which is 
representative of uremic toxins build-up, and poly (I:C), which simulates a viral 
infection. Cell viability was analyzed by a luminescence (Cell Titer Glo) assay. 
Procedure (cont.):









We have shown that it is possible to create 3D cardiomyocytes utilizing iPSCs. The qPCR results showed 
increased expression of all the cardiac markers (FOXa2, TNNT2, MYH7, AHR, CACNA1, and KCNH2) 
compared to the undifferentiated iPSCs. 
The cardiomyocytes were killed when treated with indole-3-acetate (I3A). When performing the Cell Titer 
Glo Assays, both the WTC.11 and BJFF.6 cardiomyocytes were killed in the presence of  increasing 
concentrations of I3A. Some of the data of the Cell Titer Glo Assays deviated from expected values due to 
our inability to ensure equal amounts of cells in every well. Without the ability to do this, it may appear that 
treating the BJFF.6 with 300 μM of I3A did not kill the 3D cardiomyocytes as effectively as the 150 μM. 
This may have resulted from there being more cells in the 300 μM well to begin with. This is an important 
finding because I3A concentrations have been shown to be higher in patients with chronic kidney disease, 
which is associated with cardiovascular issues. 
This experiment showed the ability to effectively differentiate cardiomyocytes from human iPSCs and 
addressed the role of the microbiome in cardiac inflammation.
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